Combination formulation of three antiviral compounds
Disclosed are pharmaceutical compositions comprising three antiviral compounds. In particular, the pharmaceutical compositions comprise an effective amount of velpatasvir, an effective amount of sofosbuvir, and an effective amount of voxilaprevir. Also disclosed are methods of use for the pharmaceutical composition.
1. A pharmaceutical dosage form comprising:
a) about 200 mg of a solid dispersion comprising about 100 mg of velpatasvir dispersed within a polymer matrix formed by a pharmaceutically acceptable polymer A, wherein the velpatasvir is substantially amorphous;
b) about 400 mg of sofosbuvir wherein the sofosbuvir is substantially crystalline; and
c) about 200 mg of a solid dispersion comprising about 100 mg of voxilaprevir dispersed within a polymer matrix formed by a pharmaceutically acceptable polymer B, wherein the voxilaprevir is substantially amorphous,
wherein the polymer A and polymer B are copovidone.
2. A tablet, comprising:
a) about 400 mg of sofosbuvir wherein the sofosbuvir is substantially crystalline;
b) about 200 mg of a solid dispersion comprising about 100 mg of velpatasvir dispersed within a polymer matrix formed by a pharmaceutically acceptable polymer A, wherein the velpatasvir is substantially amorphous; and
c) about 200 mg of a solid dispersion comprising about 100 mg of voxilaprevir dispersed within a polymer matrix formed by a pharmaceutically acceptable polymer B, wherein the voxilaprevir is substantially amorphous,
wherein the polymer A and polymer B are copovidone.